BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32669577)

  • 1. The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8
    Papagno L; Kuse N; Lissina A; Gostick E; Price DA; Appay V; Nicoli F
    Sci Rep; 2020 Jul; 10(1):11620. PubMed ID: 32669577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.
    Jiang W; Lederman MM; Harding CV; Sieg SF
    J Immunol; 2011 Feb; 186(4):2080-6. PubMed ID: 21239717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
    Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
    Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
    J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of CpG-oligodeoxynucleotides for effective activation of rabbit TLR9 mediated immune responses.
    Chuang TH; Lai CY; Tseng PH; Yuan CJ; Hsu LC
    PLoS One; 2014; 9(9):e108808. PubMed ID: 25269083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.
    Krug A; Towarowski A; Britsch S; Rothenfusser S; Hornung V; Bals R; Giese T; Engelmann H; Endres S; Krieg AM; Hartmann G
    Eur J Immunol; 2001 Oct; 31(10):3026-37. PubMed ID: 11592079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
    Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
    J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
    Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
    Front Immunol; 2019; 10():179. PubMed ID: 30800129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunostimulatory effect of CpG oligodeoxynucleotides on peripheral blood mononuclear cells of healthy dogs and dogs with atopic dermatitis.
    Jassies-van der Lee A; Rutten V; Spiering R; van Kooten P; Willemse T; Broere F
    Vet J; 2014 Apr; 200(1):103-8. PubMed ID: 24461202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.
    Wagner M; Poeck H; Jahrsdoerfer B; Rothenfusser S; Prell D; Bohle B; Tuma E; Giese T; Ellwart JW; Endres S; Hartmann G
    J Immunol; 2004 Jan; 172(2):954-63. PubMed ID: 14707068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.
    Krug A; Rothenfusser S; Selinger S; Bock C; Kerkmann M; Battiany J; Sarris A; Giese T; Speiser D; Endres S; Hartmann G
    J Immunol; 2003 Apr; 170(7):3468-77. PubMed ID: 12646607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
    Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
    Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses.
    Rudra JS; Banasik BN; Milligan GN
    Vaccine; 2018 Jan; 36(4):438-441. PubMed ID: 29248267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF.
    Abu-Rish EY; Amrani Y; Browning MJ
    Rheumatology (Oxford); 2013 Jul; 52(7):1190-201. PubMed ID: 23436580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.
    Römmler F; Hammel M; Waldhuber A; Müller T; Jurk M; Uhlmann E; Wagner H; Vollmer J; Miethke T
    PLoS One; 2015; 10(2):e0116703. PubMed ID: 25695778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.